Compare Incyte Corporation (INCY) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Motorola Solutions Inc — how do they compare? Incyte Corporation trades at $121.44 (market cap $24.54B), while Motorola Solutions Inc trades at $466.43 (market cap $77.26B). The key difference: Motorola Solutions Inc is far larger — about 3.1× Incyte Corporation's market cap, and Motorola Solutions Inc pays a 1.04% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MSI | |
|---|---|---|
Market Cap | $24.54B | $77.26B |
Sector | Health | Technology |
52-Week High | $129.93 | $490.30 |
52-Week Low | $81.61 | $363.83 |
Enterprise Value | $20.04B | $86.17B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Motorola Solutions (MSI) trades at $466.53, up 0.98% today, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.41 exceeding expectations, and the company raised its full-year guidance. Revenue growth is robust, supported by a record backlog of $15.6 billion, while profitability remains high with a net income margin of 17.44%.
The outlook is positive given strong demand in public safety and software services, though valuation multiples are elevated. Key risks include execution challenges and macroeconomic sensitivity. Analyst consensus is bullish with a $533.80 price target, implying significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
